CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.52
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.52
Open* 0.51
1-Year Change* 21.43%
Day's Range* 0.5 - 0.52
52 wk Range 0.07-2.86
Average Volume (10 days) 2.02M
Average Volume (3 months) 123.43M
Market Cap 5.83M
P/E Ratio 0.22
Shares Outstanding 71.24M
Revenue N/A
EPS 0.37
Dividend (Yield %) N/A
Beta 1.80
Next Earnings Date Mar 16, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 26, 2023 0.52 0.01 1.96% 0.51 0.53 0.50
Sep 25, 2023 0.51 -0.02 -3.77% 0.53 0.53 0.50
Sep 22, 2023 0.52 -0.03 -5.45% 0.55 0.55 0.52
Sep 21, 2023 0.55 -0.02 -3.51% 0.57 0.57 0.54
Sep 20, 2023 0.57 0.00 0.00% 0.57 0.57 0.56
Sep 19, 2023 0.56 -0.01 -1.75% 0.57 0.58 0.55
Sep 18, 2023 0.58 -0.01 -1.69% 0.59 0.60 0.57
Sep 15, 2023 0.59 -0.01 -1.67% 0.60 0.60 0.58
Sep 14, 2023 0.60 0.00 0.00% 0.60 0.63 0.58
Sep 13, 2023 0.62 -0.05 -7.46% 0.67 0.67 0.61
Sep 12, 2023 0.66 -0.03 -4.35% 0.69 0.69 0.61
Sep 11, 2023 0.70 0.00 0.00% 0.70 0.73 0.68
Sep 8, 2023 0.73 0.02 2.82% 0.71 0.78 0.68
Sep 7, 2023 0.76 -0.05 -6.17% 0.81 0.85 0.68
Sep 6, 2023 1.41 -0.13 -8.44% 1.54 1.90 1.33
Sep 5, 2023 0.66 0.01 1.54% 0.65 0.66 0.64
Sep 1, 2023 0.64 0.00 0.00% 0.64 0.65 0.62
Aug 31, 2023 0.66 0.00 0.00% 0.66 0.66 0.65
Aug 30, 2023 0.68 0.07 11.48% 0.61 0.69 0.60
Aug 29, 2023 0.62 0.02 3.33% 0.60 0.63 0.60

Palisade Bio, Inc. Events

Time (UTC) Country Event
Monday, November 13, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Palisade Bio Inc Earnings Release
Q3 2023 Palisade Bio Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 0 0.01352 0.01539 0.26 0.26
Revenue 0.01352 0.01539 0.26 0.26
Total Operating Expense 42.261 10.6891 8.64709 8.51946 13.5671
Selling/General/Admin. Expenses, Total 9.307 8.67061 4.58564 4.55927 5.47101
Research & Development 2.43 2.01845 4.06145 3.96019 8.0961
Operating Income -42.261 -10.6756 -8.6317 -8.25946 -13.3071
Interest Income (Expense), Net Non-Operating 20.635 0.02881 0.55795 3.34023 -1.55898
Other, Net -4.99 -5.62009 -0.27791 -0.00539 -0.79991
Net Income Before Taxes -26.616 -16.2668 -8.35165 -4.92462 -15.666
Net Income After Taxes -26.616 -16.2668 -8.35165 -4.92462 -15.666
Net Income Before Extra. Items -26.616 -16.2668 -8.35165 -4.92462 -15.666
Net Income -26.616 -16.2668 -8.35165 -4.92462 -15.666
Income Available to Common Excl. Extra. Items -26.616 -16.2668 -8.35165 -4.92462 -15.666
Income Available to Common Incl. Extra. Items -26.616 -16.2668 -8.35165 -4.92462 -15.666
Diluted Net Income -26.616 -16.2668 -8.35165 -4.92462 -15.666
Diluted Weighted Average Shares 9.30977 2.31155 0.36625 0.12631 0.10887
Diluted EPS Excluding Extraordinary Items -2.85893 -7.03721 -22.8034 -38.9883 -143.893
Diluted Normalized EPS 0.41977 -7.03721 -22.8034 -38.9883 -143.893
Unusual Expense (Income) 30.524
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0 0 0 0 0
Total Operating Expense 3.888 4.027 3.016 32.858 2.36
Selling/General/Admin. Expenses, Total 2.929 3.227 2.392 2.427 1.261
Research & Development 0.959 0.8 0.624 0.314 0.692
Unusual Expense (Income) 0 0 0 30.117 0.407
Operating Income -3.888 -4.027 -3.016 -32.858 -2.36
Interest Income (Expense), Net Non-Operating 0.792 5.089 12.738 4.478 -1.67
Other, Net -1.109 0.011 -1.635 -3.366 0
Net Income Before Taxes -4.205 1.073 8.087 -31.746 -4.03
Net Income After Taxes -4.205 1.073 8.087 -31.746 -4.03
Net Income Before Extra. Items -4.205 1.073 8.087 -31.746 -4.03
Net Income -4.205 1.073 8.087 -31.746 -4.03
Income Available to Common Excl. Extra. Items -4.205 1.073 8.087 -31.746 -4.03
Income Available to Common Incl. Extra. Items -4.205 1.073 8.087 -31.746 -4.03
Diluted Net Income -4.205 1.073 8.087 -31.746 -4.03
Diluted Weighted Average Shares 16.2237 13.5328 12.1068 8.9842 7.43177
Diluted EPS Excluding Extraordinary Items -0.25919 0.07929 0.66797 -3.53354 -0.54227
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.25919 0.07929 0.66797 -0.18132 -0.4875
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 12.374 12.8808 5.64688 6.50839 12.4488
Cash and Short Term Investments 10.495 10.5292 5.11492 5.78711 11.6749
Cash & Equivalents 10.495 10.5292 5.11492 5.78711 6.67494
Short Term Investments 0 5
Total Receivables, Net 0.15 0.11628 0.02106 0.358 0.37159
Accounts Receivable - Trade, Net 0 0.11628 0.02106 0.29406 0.3128
Prepaid Expenses 1.703 1.39979 0.5109 0.36329 0.40227
Total Assets 12.512 13.0491 6.58389 7.68445 13.8845
Property/Plant/Equipment, Total - Net 0.112 0.01078 0.04104 0.09031 0.17289
Property/Plant/Equipment, Total - Gross 0.99145 0.99481
Accumulated Depreciation, Total -0.95042 -0.82193
Intangibles, Net 0.14713 0.66894 0.76354 0.88346
Note Receivable - Long Term 0 0.29824 0.36546
Other Long Term Assets, Total 0.026 0.01044 0.22704 0.02397 0.01385
Total Current Liabilities 2.496 3.20593 1.22476 1.05117 1.51457
Payable/Accrued 0.64935 0.82441 0.83256 0.87507
Accrued Expenses 1.086 2.32224 0.13569 0 0.41863
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.087 0
Other Current Liabilities, Total 0.23434 0.26467 0.2186 0.22088
Total Liabilities 5.147 3.28123 1.4579 1.6349 5.36933
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0
Other Liabilities, Total 2.651 0.0753 0.23314 0.58373 3.85476
Total Equity 7.365 9.76792 5.12599 6.04955 8.51513
Preferred Stock - Non Redeemable, Net 0.002 0.002 0.002 0.01 0.01
Common Stock 0.143 0.17296 0.03867 0.18205 0.1516
Additional Paid-In Capital 101.862 247.836 227.067 219.482 217.05
Retained Earnings (Accumulated Deficit) -94.642 -238.242 -221.976 -213.624 -208.699
Other Equity, Total -0.00073 -0.00619 -0.00041 0.00263
Total Liabilities & Shareholders’ Equity 12.512 13.0491 6.58389 7.68445 13.8845
Total Common Shares Outstanding 14.2392 2.88268 0.64442 0.15171 0.12634
Total Preferred Shares Outstanding 0.2 0.2 0.2 1 1
Other Current Assets, Total 0.026 0.83548
Accounts Payable 1.323
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 8.258 12.374 16.092 14.725 8.7556
Cash and Short Term Investments 6.644 10.495 14.104 12.653 6.56095
Cash & Equivalents 6.644 10.495 14.104 12.653 6.56095
Total Receivables, Net 0.086 0 0 0.059 0.02526
Accounts Receivable - Trade, Net 0 0 0.059 0.02526
Prepaid Expenses 1.42 1.879 1.988 2.013 1.30869
Other Current Assets, Total 0.108 0.8607
Total Assets 8.35 12.512 16.274 14.949 8.91492
Property/Plant/Equipment, Total - Net 0.066 0.112 0.156 0.198 0.00724
Intangibles, Net 0.14164
Other Long Term Assets, Total 0.026 0.026 0.026 0.026 0.01044
Total Current Liabilities 1.864 2.496 2.92 3.85 1.01493
Payable/Accrued 0.52091
Accrued Expenses 0.717 1.086 0.969 1.303 0.31626
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.17776
Total Liabilities 3.558 5.147 12.354 24.393 1.18613
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 1.694 2.651 9.434 20.543 0.1712
Total Equity 4.792 7.365 3.92 -9.444 7.72879
Preferred Stock - Non Redeemable, Net 0.002 0.002 0.002 0.002 0.002
Common Stock 0.183 0.143 0.13 0.114 0.02883
Additional Paid-In Capital 103.454 101.862 99.503 94.242 248.228
Retained Earnings (Accumulated Deficit) -98.847 -94.642 -95.715 -103.802 -240.527
Other Equity, Total -0.00278
Total Liabilities & Shareholders’ Equity 8.35 12.512 16.274 14.949 8.91492
Total Common Shares Outstanding 18.2335 14.2392 12.9299 11.3987 2.88262
Total Preferred Shares Outstanding 0.2 0.2 0.2 0.2 0.2
Accounts Payable 1.147 1.323 1.383 1.406
Current Port. of LT Debt/Capital Leases 0 0.087 0.568 1.141
Long Term Debt 0 0 0
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -26.616 -16.2668 -8.35165 -4.92462 -15.666
Cash From Operating Activities -14.773 -9.02513 -7.25568 -7.69242 -13.4162
Cash From Operating Activities 0.002 0.09227 0.14386 0.1858 0.28921
Non-Cash Items 16.597 6.19578 0.74383 -2.61672 4.11447
Cash Taxes Paid 0
Changes in Working Capital -4.756 0.95364 0.20829 -0.33688 -2.15385
Cash From Investing Activities -0.054 0 4.99829 -0.09405
Capital Expenditures 0 -0.00171 -0.09405
Other Investing Cash Flow Items, Total -0.054 0 5 0
Cash From Financing Activities 24.609 14.4659 6.58951 1.81423 4.99078
Financing Cash Flow Items -0.218
Issuance (Retirement) of Stock, Net 25.01 14.6982 6.55308 1.828 8.73602
Issuance (Retirement) of Debt, Net -0.183 -0.2323 0.03643 -0.01377 -3.74524
Foreign Exchange Effects -0.00119 -0.00602 -0.00793 -0.00058
Net Change in Cash 9.782 5.4396 -0.67219 -0.88783 -8.52001
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -4.205 -26.616 -27.689 -35.776 -2.28508
Cash From Operating Activities -3.764 -14.773 -11.718 -8.972 -3.94124
Cash From Operating Activities 0.001 0.002 0.002 0.002 0.00903
Non-Cash Items 0.72 16.597 21.342 32.167 0.3439
Changes in Working Capital -0.28 -4.756 -5.373 -5.365 -2.00908
Cash From Investing Activities 0 -0.054 -0.054 0.294 0
Other Investing Cash Flow Items, Total 0 -0.054 -0.054 0.294 0
Cash From Financing Activities -0.087 24.609 25.163 20.618 0
Issuance (Retirement) of Stock, Net 25.01 25.01 19.801 0
Issuance (Retirement) of Debt, Net -0.087 -0.183 0.301 0.965 0
Foreign Exchange Effects -0.00104
Net Change in Cash -3.851 9.782 13.391 11.94 -3.94228
Capital Expenditures 0
Financing Cash Flow Items -0.218 -0.148 -0.148

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Palisade Bio, Inc. Company profile

About Palisade Bio Inc

Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Palisade Bio Inc revenues decreased from $11K to $0K. Net loss increased from $11.8M to $27.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest expense increase from $14K to $2.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$7.31 to -$3.41.

Equity composition

Common Stock $.01 Par, 03/11, 150M auth., 48,366,304 shares issd. Insiders & Strategic holders own 13.61%. IPO:1/07, 16.3M shares @ $1 per Share.

Industry: Biotechnology & Medical Research (NEC)

7750 El Camino Real, Suite 5200
92009

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

BTC/USD

26,283.95 Price
+0.330% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

ETH/USD

1,601.15 Price
+0.720% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Oil - Crude

92.99 Price
+3.160% 1D Chg, %
Long position overnight fee 0.0587%
Short position overnight fee -0.0806%
Overnight fee time 21:00 (UTC)
Spread 0.030

US100

14,508.90 Price
-0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading